Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Tirzepatide has emerged as the most effective treatment for lowering blood sugar and promoting weight loss in people with ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...